Abstract: Objective s To evaluate the efficacy of combination sofosbuvir and pegylated interferon-α in the treatment of patients chronic hepatitis C（CHC）. Methods We searched PUBMED,Cochrane Library,CNKI,CBM,VIP database for studies on combination sofosbuvir and pegylated interferonα versus sofosbuvir or pegylated interferon-α therapy in patients with CHC up to Mar. 2017. We performed the Meta-analysis by using the Revman 5.2. Results Nine studies were finally obtained including 827 patients with CHC,5 studies reported the observation between SOF/PEG-IFN/RBV （n=339） and SOF/RBV （n=269） and 4 studies reported the viral response between SOF/PEG-IFN/RBV（n=105） and PEG-IFN/RBV（n=114）. The results of Meta-analysis showed that the RVR in SOF/PEG-IFN/RBV group was higher than in SOF/RBV or in PEG-IFN/RBV group（86.7% vs. 71.7%,P=0.002 and 91.7% vs. 32.3%,P=0.006）;the SVR in SOF/PEG-IFN/RBV group was higher than in PEG-IFN/RBV group（85.7% vs. 44.2%,P<0.00001）,while there was no statistical difference between SOF/PEG-IFN/RBV group and SOF/RBV group（89.0% vs. 74.1%,P=0.16）;the adverse events,such as headache,fatigue,nausea,rash,muscle pain,decreased appetite,arthralgia,fever and anemia in SOF/PEG-IFN/RBV group was higher than in SOF/RBV group. Conclusion The efficacy of combination treatment of SOF/PEG-IFN/RBV is better than SOF/RBV or PEG-IFN/RBV with higher RVR or SVR for patients with CHC.

Key words: Chronic hepatitis C, Sofosbuvir, Pegylated interferon-α, Ribavirin, Meta-analysis